WQ 0835

Drug Profile

WQ 0835

Latest Information Update: 02 Jun 1998

Price : $50

At a glance

  • Originator Wakunaga Pharmaceutical
  • Class Antibacterials; Quinolones
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 02 Jun 1998 Discontinued-Preclinical for Bacterial infections in Japan (PO)
  • 26 Oct 1995 New profile
  • 12 Oct 1995 Preclinical development for Bacterial infections in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top